Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of the Combination of Alsertib (MLN8237) and Brentuximab Vedotin in Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies

NCT02780011 is registered in ClinicalTrials.gov with Eric Bernicker, MD as lead sponsor.

NCT NCT02780011
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02780011 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of the Combination of Alsertib (MLN8237) and Brentuximab Vedotin in Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies
Lead sponsor
Eric Bernicker, MD
Phase
Phase 1
Overall status
Withdrawn
Start date
December 31, 2015
Completion date
September 30, 2018
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cd30-positive lymphoma, cd30-positive solid tumor